comscore U.S. to spend $3.2B for antiviral pills for COVID-19 | Honolulu Star-Advertiser
Top News

U.S. to spend $3.2B for antiviral pills for COVID-19

  • JIM LO SCALZO/POOL PHOTO VIA ASSOCIATED PRESS
                                Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, spoke, May 11, during a hearing on Capitol Hill in Washington. The United States is devoting more than $3 billion to advance the development of antiviral pills for COVID-19, according to an official briefed on the matter.

    JIM LO SCALZO/POOL PHOTO VIA ASSOCIATED PRESS

    Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, spoke, May 11, during a hearing on Capitol Hill in Washington. The United States is devoting more than $3 billion to advance the development of antiviral pills for COVID-19, according to an official briefed on the matter.

WASHINGTON >> The United States is devoting $3.2 billion to advance the development of antiviral pills for COVID-19 and other dangerous viruses that could turn into pandemics.

Dr. Anthony Fauci, the nation’s top infectious disease expert, announced the investment today at a White House briefing as part of a new “antiviral program for pandemics” to develop drugs to address symptoms caused by potentially dangerous viruses like the coronavirus.

The funding will speed those clinical trials and provide additional support to private sector research, development and manufacturing.

Fauci said the new program would invest in “accelerating things that are already in progress” for COVID-19 but also would work to innovate new therapies for other viruses.

“There are few treatments that exist for many of the viruses that have pandemic potential,” he said.

But he added, “vaccines clearly remain the centerpiece of our arsenal.”

The U.S. has approved one antiviral drug, remdesivir, against COVID-19 and allowed emergency use of three antibody combinations that help the immune system fight the virus. But all the drugs have to be infused at hospitals or medical clinics, and demand has been low due to these logistical hurdles.

The U.S. government has been trying to raise awareness of the treatments, connecting people who test positive for COVID-19 with information about nearby providers.

Health experts, including Fauci, have increasingly called for simpler pill-based drugs that patients could take themselves. Some drugmakers are testing such medications, but initial results aren’t expected for several more months.

The currently available drugs have mostly been shown to help patients avoid hospitalization or shorten their recovery time by several days.

Under President Donald Trump, the U.S. poured more than $19 billion into rapidly developing multiple vaccines. But less than half that amount went toward developing new treatments. That shortfall has become increasingly concerning as the vaccination campaign slows and experts emphasize the need to manage the disease in millions of Americans who may never get inoculated.

The biggest need is for a convenient pill that can help keep patients with early symptoms of COVID-19 from developing severe disease and needing hospitalization.

Several companies, including Pfizer, Roche and AstraZeneca, are testing antivirals in pill form.

Until this week, the only medicines shown to boost survival were steroids given to patients sick enough to need extra oxygen and intensive care. But on Wednesday, U.K. researchers reported that one of the antibody combinations successfully reduced deaths in a large study of hospitalized COVID-19 patients.

News of the Biden administration’s plans for the antiviral pills was first reported by The New York Times.

Comments (8)

By participating in online discussions you acknowledge that you have agreed to the Terms of Service. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. Report comments if you believe they do not follow our guidelines.

Having trouble with comments? Learn more here.

Click here to see our full coverage of the coronavirus outbreak. Submit your coronavirus news tip.

Be the first to know
Get web push notifications from Star-Advertiser when the next breaking story happens — it's FREE! You just need a supported web browser.
Subscribe for this feature

Scroll Up